1. Home
  2. SLN

SLN

Silence Therapeutics Plc American Depository Share

Logo Silence Therapeutics Plc American Depository Share

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-12-2024 4:00pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid. its pipeline products are; SLN360 therapy designed to temporarily block a specific gene's message that would otherwise trigger an unwanted effect. By silencing the LPA gene, the levels of Lp(a) are lowered, which in turn is expected to lower the risks of heart diseases, heart attacks, and strokes, and SLN124 therapy aims to temporarily silence TMPRSS6, a gene that prevents the liver from producing a particular hormone that controls iron levels in the body hepcidin. As hepcidin increases, iron levels in the blood are expected to decrease, which may increase the production of healthy red blood cells, thereby reducing anemia.

Founded: N/A Country:
United Kingdom
United Kingdom
Employees: N/A City: N/A
Market Cap: 983.5M IPO Year: N/A
Target Price: $57.25 AVG Volume (30 days): 256.1K
Analyst Decision: Strong Buy Number of Analysts: 4
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -1.47 EPS Growth: N/A
52 Week Low/High: $4.55 - $27.72 Next Earning Date: 05-14-2024
Revenue: $32,120,253 Revenue Growth: 44.99%
Revenue Growth (this year): -37.82% Revenue Growth (next year): 104.98%

Share on Social Networks: